Skip to main content
. 2015 Sep 30;6(34):35183–35201. doi: 10.18632/oncotarget.5930

Figure 4. miR-145-5p impairs the expression of EGFR protein.

Figure 4

A. Immunohistochemistry for EGFR in 2 representative patients slides (pt=patient). B. Quantification of positive EGFR staining in tissues. C. Western-blot analysis of EGFR protein expression in H1299 cells upon miR-145-5p over-expression. D. Renilla luciferase activity of EGFR-3′UTR reporter gene in H1299 transiently transfected with miR-145-5p mimic or control mimic. E. qRT-PCR analysis of EGFR mRNA levels in H1299 cells upon 5 uM vorinostat (SAHA) treatment. F. Western-blot analysis of EGFR in H1299, MDA-231 and M14 cells upon 24 hours of vorinostat (SAHA) treatments. G. Quantification of immunofluorescence assay to analyze EGFR localization in H1299 cells treated with EGF (20 ng/mL) upon miR-145-5p over-expression. H. Analysis of pEGFR protein expression levels in H1299 cells treated with EGF (20 ng/mL) or maintained in serum free (Sf) medium upon miR-145-5p over-expression. I. c-Met protein levels in H1299 cells treated with EGF (20 ng/mL) or maintained in serum free (Sf) medium upon miR-145-5p over-expression. L. Quantification of immunofluorescence assay to analyze EGFR localization in H1299 cells treated with EGF (20 ng/mL) upon MUC-1 RNA interference.